NCT02671435: A Study of Durvalumab (MEDI4736) and IPH2201 in Solid Tumors

NCT02671435
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1|Ph+ase 2
Drug Category: Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 99 Years (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: 
https://ClinicalTrials.gov/show/NCT02671435

Comments are closed.

Up ↑